Comparator Drug Sourcing for UK Clinical Trials: A 2026 Sponsor and CRO Guide

In almost every controlled clinical trial, the investigational treatment is measured against something. That something is the comparator, and getting hold of it, in the right quantity, from consistent batches, with enough shelf life and the right paperwork, is one of the quieter but more persistent headaches in clinical supply. Sponsors and contract research organisations plan the science in fine detail, then discover that securing a steady supply of an ordinary licensed medicine to sit alongside the study drug is anything but ordinary.

This guide is written for clinical-trial sponsors, CRO clinical supply teams and clinical supply managers who need to source comparator and reference products through the UK. It explains what a comparator is, why sourcing it is harder than it looks, how a UK MHRA-licensed wholesale exporter fits into the supply chain, and where the responsibilities of the wholesaler end and the sponsor's Investigational Medicinal Product (IMP) obligations begin.

One boundary is worth stating clearly up front. Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter holding Wholesale Dealer Authorisation WDA(H) 59239. We source and supply genuine, UK-licensed, MHRA-authorised finished medicines from the UK commercial market. We are not a manufacturer, an IMP manufacturer, or a packaging, labelling or Qualified Person release house. When a commercial medicine is turned into trial supply, through blinding, re-labelling or certification, that work belongs to the sponsor and their IMP manufacturer. Our role is the compliant sourcing and GDP distribution of the licensed comparator product that feeds into that process.

What a Comparator Is in a Clinical Trial

A comparator is the reference against which the effect of the investigational medicine is judged. Its purpose is to give the trial a fair, interpretable baseline. There are a few common forms:

• Active comparator. An approved medicine already used in standard care, chosen because it represents the current benchmark treatment. This is the most common type Euro Biom is asked to source, and it is typically a licensed, commercially available finished product.
• Placebo. An inactive preparation used where a placebo-controlled design is scientifically and ethically justified. Placebo is usually produced or matched by the sponsor's IMP manufacturer rather than sourced commercially.
• Standard-of-care regimen. In some designs the comparator is the existing treatment pathway, which may involve one or more licensed background medicines.

Regulators and protocols often group the comparator together with background, rescue and challenge medicines under headings such as auxiliary or non-investigational medicinal products. The precise classification is a matter for the sponsor's regulatory and quality functions. What matters for sourcing is that, in practice, the comparator is very often a licensed, marketed medicine that has to be bought in rather than made. That is where a wholesaler comes in: Euro Biom supplies the UK-licensed comparator as a finished medicine, while the sponsor and their IMP manufacturer handle whatever downstream steps are needed to make it trial-ready.

Why Comparator Sourcing Is Difficult

On paper, buying a licensed medicine sounds trivial. In a trial context it rarely is. Four pressures make it genuinely difficult.

1. Batch consistency

A trial wants the comparator to be a constant, not a variable. Ideally the comparator comes from a single batch, or a small and controlled number of batches, so that lot-to-lot variation does not creep into the data or complicate the blinding. Ordinary wholesale supply is not organised around that requirement, so it takes a supplier willing to reserve and track specific batches to meet it.

2. Shelf life and expiry

Comparator has to cover the whole treatment period, plus contingency for slower-than-expected recruitment and resupply. Product that arrives with only a few months of remaining shelf life is a liability, because it may expire mid-study and force an unplanned resupply and re-labelling cycle. Sourcing has to be built around remaining shelf life, not just availability.

3. Documentation depth

Routine hospital supply needs a delivery note. Trial supply needs a documentation trail that will satisfy the sponsor's Qualified Person and stand up to a regulatory inspection: provenance within the licensed chain, batch and expiry data, and certificates where the manufacturer makes them available. A supplier that treats paperwork as an afterthought creates work and risk downstream.

4. Forecasting and availability

Trials run across multiple sites and often multiple countries, with demand that flexes as recruitment moves. At the same time, the specific comparator product can be subject to shortages, allocation limits or discontinuation. Matching a moving demand curve against a constrained product is a forecasting exercise, not a one-off purchase.

Sourcing Comparators from the UK Market

The UK is a strong origin for comparator supply. It has a mature, tightly regulated wholesale sector, MHRA oversight of the whole distribution chain, and, through Heathrow, fast international connectivity. For a sponsor or CRO, sourcing a comparator as an open-label commercial product through a UK Wholesale Dealer Authorisation holder means the medicine is a genuine, UK-licensed finished product bought within the legitimate supply chain, with the audit trail that goes with it.

The model is straightforward. Euro Biom procures the UK-licensed comparator product from the UK commercial market under its WDA, holds or reserves it as required, and supplies it, with documentation, to the sponsor's nominated IMP manufacturer, central supply depot or distribution partner. From there, the sponsor's IMP manufacturer performs any blinding, over-encapsulation, re-labelling, repackaging and Qualified Person certification needed to convert the commercial product into finished trial supply.

That division of labour is deliberate and important. It keeps the licensed product within a compliant sourcing and distribution chain up to the point of handover, and it keeps IMP manufacturing and release, which are regulated activities requiring the appropriate manufacturing authorisation, firmly with the parties licensed to perform them. Euro Biom does not blind, re-label or certify trial supply, and does not hold itself out as able to. For the wider service picture, see our clinical trials supply and comparator drug sourcing pages.

Documentation and Traceability

Documentation is where comparator sourcing is won or lost. The sponsor's Qualified Person has to be able to satisfy themselves about the identity, provenance and quality of the comparator before it enters the trial supply chain, and an inspector has to be able to follow the audit trail. A UK-licensed comparator supplied through a WDA holder should arrive with a coherent evidence package. The table below sets out the core elements and who is responsible for each.

Two points sit behind that table. First, the wholesaler's documentation supports, but does not replace, the sponsor's own quality assessment. Euro Biom provides the sourcing and distribution evidence; the Qualified Person certification of the finished trial supply is a separate, regulated step that stays with the sponsor and their IMP manufacturer. Second, the strength of the package depends partly on what the manufacturer releases: a Certificate of Analysis is provided where it is obtainable for the batch, and where it is not, batch and provenance documentation still support the trail. For the broader documentation picture on the UK export side, see our guide to UK pharmaceutical import documentation.

Supply Continuity Across a Trial

A comparator that is available on day one but unobtainable in month eight is a problem that has simply been deferred. Continuity has to be designed in. The main levers are forecasting, buffer stock and expiry management.

Forecasting. Working from the sponsor's projected recruitment and dosing schedule, sourcing can be planned against the demand for the treatment period rather than bought reactively. A realistic forecast, updated as recruitment data comes in, is the single most useful input a sponsor can give a comparator supplier.

Buffer stock. Holding or reserving a contingency margin above the base forecast absorbs the two things that reliably go wrong: recruitment that outpaces the plan, and resupply lead times that are longer than hoped. Where the comparator product is subject to shortage or allocation, an early reservation is often the difference between continuity and a gap.

Expiry management. Reserved stock has to be rotated and monitored so that product is used or replaced before it expires. Managing expiry actively, rather than discovering it at the point of use, avoids the disruptive cycle of emergency resupply and re-labelling that a lapsed batch triggers.

Because Euro Biom operates from near Heathrow, urgent top-ups can be despatched quickly when a site recruits faster than expected. The practical goal is simple to state and harder to deliver: a trial site should never run short of comparator during the study. For related supply-continuity thinking, see our drug shortages guide.

Cold Chain and GDP for Trial Supply

Where a comparator is temperature sensitive, Good Distribution Practice and a validated cold chain are part of what keeps the product usable and the audit trail intact on the UK leg. The controls that matter are the same ones that govern any compliant temperature-controlled shipment, applied with the extra rigour a trial demands:

• Validated temperature-controlled storage in the UK at the labelled storage condition before despatch.
• Qualified shipping containers appropriate to the route and the ambient conditions expected in transit, including warmer summer ground temperatures.
• Continuous temperature monitoring with a calibrated data logger accompanying the consignment, so the temperature history is available for review on arrival.
• A documented deviation procedure agreed in advance, so that any temperature excursion is handled and assessed rather than leaving a consignment in limbo.

Euro Biom operates the GDP-compliant UK leg, from validated storage through to despatch. Onward handling by the IMP manufacturer, and the release decision on any excursion affecting trial supply, sit with the sponsor's quality chain. For more on the logistics, see our UK cold chain pharmaceutical supply page and the pharma cold chain logistics guide.

How Euro Biom Supports Sponsors and CROs

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines, and for clinical-trial supply our role is the sourcing and GDP distribution of the comparator product. Working with sponsors, CROs and their IMP manufacturers, that role typically covers:

• Comparator sourcing. Procuring the UK-licensed comparator product from the UK commercial market under our WDA, with attention to batch consistency and remaining shelf life.
• Documentation. Supplying proof of purchase and provenance, batch and expiry data, Certificate of Analysis or batch documentation where obtainable, and GDP chain-of-custody records to support the sponsor's Qualified Person assessment.
• Continuity. Sourcing against the sponsor's forecast, reserving buffer stock, and monitoring expiry so that supply holds across the treatment period.
• Cold-chain logistics. GDP-validated temperature-controlled storage, qualified containers, calibrated loggers, and despatch from near Heathrow, for both UK and international lanes.

Equally important is what we do not do. We do not manufacture, blind, over-encapsulate, re-label or perform Qualified Person certification of trial supply. Those IMP activities are the responsibility of the sponsor and their IMP manufacturer. By keeping our contribution to compliant sourcing and distribution of the licensed comparator, we give the trial's quality chain a clean, well-documented input to build on. For more, see our clinical trials supply page and an overview of our services.